TITLE

ORTEC SUCCESSFULY DEFENDS EUROPEAN PATENT ON ORCEL

PUB. DATE
May 2002
SOURCE
Worldwide Biotech;May2002, Vol. 14 Issue 5, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that Ortec International has successfully defended an opposition filed with the European Patent Office by Advanced Tissue Sciences Inc. challenging the validity of Ortec's patent on OrCel tissue engineering platform technology.
ACCESSION #
6589537

 

Related Articles

  • NYC's BIOTECH DISGRACE. Messina, Judith // Crain's New York Business;8/27/2001, Vol. 17 Issue 35, p11 

    Focuses on government initiatives in promoting biotechnology industry in New York, New York. Plan of biotech firm Ortec International Inc.to build a manufacturing plant; Comparison on the biotechnology developments between New York City and other cities; Inability of the city to provide...

  • IOPs hit cruising altitude, but turbulence lies ahead. Temes, Judy // Crain's New York Business;01/20/97, Vol. 13 Issue 3, p19 

    Presents information on Ortec International Incorporated a bio-medical company and its financial status for 1996. Why product was not approved by the Food and Drug Administration (FDA); Statistical information on the New York Area Initial Public Offering (IPO).

  • New skin helps burn victims, NY start-up. Goldstein, Matthew // Crain's New York Business;02/16/98, Vol. 14 Issue 7, p18 

    Looks at Ortec International Incorporated, a biotechnology company in New York, and its `composite cultured skin,' which was designed to help burn victims. When the company went public; Reference to more funds needed; Comments from Anthony G. Viscogliosi, an analyst at the investment firm...

  • FDA FILINGS.  // Materials Management in Health Care;May2001, Vol. 10 Issue 5, p9 

    Reports on the approval by the United States Food and Drug Administration on composite cultured skin useful in reconstructive hand surgery made by Ortec International in New York, New York.

  • Surgical Briefs.  // Dermatology Times;Mar2002, Vol. 23 Issue 3, p57 

    Reports developments on surgery as of March 2002. Plans of the tissue engineer Ortec International to forward results from the follow-up test on patients with venous ulcer pilot trials to the U.S. Food and Drug Administration; Court ruling on the presence of anesthesiologist during the major...

  • ORTEC COMPLETES PATIENT ENROLLMENT IN DONOR SITE STUDY.  // Biotech Business;Jul2000, Vol. 13 Issue 7, p1 

    Reports that Ortec International Inc. has met its projected enrollment goals and completed enrollment in its donor site study which focused on the application of its Composite Cultured Skin in wound healing.

  • Greener Pastures.  // Business News New Jersey;02/11/2002, Vol. 15 Issue 7, p4 

    Reports the relocation of Ortec International to the Technology Centre of New Jersey in North Brunswick. Investments made the center in preparation for the transfer; Advantage gained by the company.

  • Engineered tissue successfully heals diabetic ulcers over 12 weeks.  // Dermatology Times;Dec2001, Vol. 22 Issue 12, p27 

    Focuses on the improvement of standard of care for diabetic ulcers. Development of OrCel engineered tissue by Ortec International; Percentage of patients treated with OrCel achieving total wound closure; Daily rate of healing for OrCel-treated patients.

  • Ortec Files for FDA Market Approval for Novel Tissue Product.  // Biotech Business;Jan2000, Vol. 13 Issue 1, p6 

    Reports that Ortec International Inc. filed for United States Food and Drug Administration approval to begin marketing its tissue product to treat four critical skin diseases.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics